Metabolic Changes in Tumor Cells and Tumor-associated Macrophages: A Mutual Relationship
Overview
Affiliations
In order to adapt to the reduced availability of nutrients and oxygen in the tumor microenvironment and the increased requirements of energy and building blocks necessary for maintaining their high proliferation rate, malignant cells undergo metabolic changes that result in an increased production of lactate, nitric oxide, reactive oxygen species, prostaglandins and other byproducts of arachidonic acid metabolism that influence both the composition of the inflammatory microenvironment and the function of the tumor-associated macrophages (TAMs). In response to cues present in the TME, among which products of altered tumor cell metabolism, TAMs are also required to reprogram their metabolism, with activation of glycolysis, fatty acid synthesis and altered nitrogen cycle metabolism. These changes result in functional reprogramming of TAMs which includes changes in the production of cytokines and angiogenetic factors, and contribute to the tumor progression and metastasis. Understanding the metabolic changes governing the intricate relationship between the tumor cells and the TAMs represents an essential step towards developing novel therapeutic approaches targeting the metabolic reprogramming of the immune cells to potentiate their tumoricidal potential and to circumvent therapy resistance.
Lipid Metabolism in Breast Cancer: From Basic Research to Clinical Application.
Huang X, Liu B, Shen S Cancers (Basel). 2025; 17(4).
PMID: 40002245 PMC: 11852908. DOI: 10.3390/cancers17040650.
Guo Z, Ma J, Zhang J, Yan L, Zhou Y, Mao X Front Immunol. 2025; 16:1524801.
PMID: 39925801 PMC: 11802498. DOI: 10.3389/fimmu.2025.1524801.
Metabolic features of tumor-derived extracellular vesicles: challenges and opportunities.
Espiau-Romera P, Gordo-Ortiz A, Ortiz-de-Solorzano I, Sancho P Extracell Vesicles Circ Nucl Acids. 2024; 5(3):455-470.
PMID: 39697624 PMC: 11648520. DOI: 10.20517/evcna.2024.12.
Harnessing glucose metabolism with nanomedicine for cancer treatment.
Wang X, Wang L, Hao Q, Cai M, Wang X, An W Theranostics. 2024; 14(17):6831-6882.
PMID: 39479443 PMC: 11519798. DOI: 10.7150/thno.100036.
Glibetic N, Bowman S, Skaggs T, Weichhaus M Int J Mol Sci. 2024; 25(19).
PMID: 39408832 PMC: 11477048. DOI: 10.3390/ijms251910503.